Further evidence for the involvement of tachykinin receptor subtypes in formalin and capsaicin models of pain in mice

[1]  A. Dray,et al.  Novel pharmacological strategies for analgesia. , 1996, Annals of the rheumatic diseases.

[2]  J. Calixto,et al.  Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice. , 1996, European journal of pharmacology.

[3]  C. Bertrand,et al.  Tachykinin and kinin receptor antagonists: therapeutic perspectives in allergic airway disease. , 1996, Trends in pharmacological sciences.

[4]  R. Yunes,et al.  Antinociceptive action of 2-(4-bromobenzoyl)-3-methyl-4,6-dimethoxy benzofuran, a novel xanthoxyline derivative on chemical and thermal models of nociception in mice. , 1996, The Journal of pharmacology and experimental therapeutics.

[5]  J. Calixto,et al.  Antinociceptive profile of the pseudopeptide B2 bradykinin receptor antagonist NPC 18688 in mice , 1996, British journal of pharmacology.

[6]  C. Whitty,et al.  Neurokinin-3 receptors modulate dopamine cell function and alter the effects of 6-hydroxydopamine , 1995, Brain Research.

[7]  C. Maggi,et al.  The mammalian tachykinin receptors. , 1995, General pharmacology.

[8]  P. Soubrié,et al.  Functional characterization of the nonpeptide neurokinin3 (NK3) receptor antagonist, SR142801 on the human NK3 receptor expressed in Chinese hamster ovary cells. , 1995, The Journal of pharmacology and experimental therapeutics.

[9]  C. Maggi,et al.  Activity of SR 142801 at peripheral tachykinin receptors. , 1995, European journal of pharmacology.

[10]  M. Millan,et al.  Antinociceptive profiles of non-peptidergic neurokinin1 and neurokinin2 receptor antagonists: a comparison to other classes of antinociceptive agent , 1995, Pain.

[11]  T. Yaksh,et al.  Cyclooxygenase inhibition and the spinal release of prostaglandin E2 and amino acids evoked by paw formalin injection: a microdialysis study in unanesthetized rats , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[12]  C. Maggi,et al.  Peptide‐based tachykinin NK2 receptor antagonists , 1995, Medicinal research reviews.

[13]  M. Poncelet,et al.  SR 142801, the first potent non-peptide antagonist of the tachykinin NK3 receptor. , 1994, Life sciences.

[14]  C. Maggi,et al.  Tachykinin receptors and receptor subtypes. , 1995, Archives internationales de pharmacodynamie et de therapie.

[15]  R. Pauwels,et al.  Characterization of the neurogenic plasma extravasation in the airways. , 1995, Archives internationales de pharmacodynamie et de therapie.

[16]  J. Fauchère,et al.  Receptors and antagonists for substance P and related peptides. , 1994, Pharmacological reviews.

[17]  N. Rupniak,et al.  Differential inhibition of foot tapping and chromodacryorrhoea in gerbils by CNS penetrant and non-penetrant tachykinin NK1 receptor antagonists. , 1994, European journal of pharmacology.

[18]  R. Dubner,et al.  Inflammation and hyperalgesia in rats neonatally treated with capsaicin: effects on two classes of nociceptive neurons in the superficial dorsal horn , 1994, Pain.

[19]  D. McDonald,et al.  Direct observation of substance P-induced internalization of neurokinin 1 (NK1) receptors at sites of inflammation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Blanchard,et al.  Differential ability of tachykinin NK-1 and NK-2 agonists to produce scratching and grooming behaviours in mice , 1994, Brain Research.

[21]  A. Dickenson,et al.  Pharmacology of chronic pain. , 1994, Trends in pharmacological sciences.

[22]  T. Mizuguchi,et al.  Effects of intrathecal FK888, a novel dipeptide NK1 receptor antagonist, on the formalin test in the rat , 1993, Neuroscience Letters.

[23]  K. Tan-No,et al.  Antinociceptive effects in the formalin and capsaicin tests after intrathecal administration of substance P analogues in mice. , 1993, European journal of pharmacology.

[24]  J. Calixto,et al.  Evidence for participation of B1 and B2 kinin receptors in formalin‐induced nociceptive response in the mouse , 1993, British journal of pharmacology.

[25]  A. Dickenson,et al.  The effect of intrathecal administration of RP67580, a potent neurokinin 1 antagonist on nociceptive transmission in the rat spinal cord , 1993, Neuroscience Letters.

[26]  A. Murase,et al.  Non-specific activity of (±)CP-96,345 in models of pain and inflammation , 1993, Regulatory Peptides.

[27]  E. Burcher,et al.  Tachykinin Receptors: A Radioligand Binding Perspective , 1993, Journal of neurochemistry.

[28]  A I Basbaum,et al.  Peptides and the primary afferent nociceptor , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[29]  R. Amann,et al.  The inhibition of neurogenic inflammation. , 1993, General pharmacology.

[30]  K. Yoshioka,et al.  Neurotransmitter functions of mammalian tachykinins. , 1993, Physiological reviews.

[31]  K. Tan-No,et al.  Antinociception induced by CP 96,345, a non-peptide NK-1 receptor antagonist, in the mouse formalin and capsaicin tests , 1993, Neuroscience Letters.

[32]  P. Laduron,et al.  Antinociceptive properties and inhibition of neurogenic inflammation with potent SP antagonists belonging to perhydroisoindolones , 1992, Regulatory Peptides.

[33]  K. Tan-No,et al.  Spantide-induced antinociception in the opioid mechanism , 1992, Regulatory Peptides.

[34]  C. Strader,et al.  Molecular basis for the species selectivity of the neurokinin-1 receptor antagonists CP-96,345 and RP67580. , 1992, The Journal of biological chemistry.

[35]  K. Tan-No,et al.  The capsaicin test in mice for evaluating tachykinin antagonists in the spinal cord , 1992, Neuropharmacology.

[36]  A. Dray.  Neuropharmacological mechanisms of capsaicin and related substances. , 1992, Biochemical pharmacology.

[37]  A. Dray.  Mechanism of action of capsaicin-like molecules on sensory neurons. , 1992, Life sciences.

[38]  S. Watson,et al.  Tachykinin receptor types: Classification and membrane signalling mechanisms , 1991, Neurochemistry International.

[39]  R. B. Carter.  Topical capsaicin in the treatment of cutaneous disorders , 1991 .

[40]  T. Yamamoto,et al.  Stereospecific effects of a nonpeptidic NK1 selective antagonist, CP-96,345: antinociception in the absence of motor dysfunction. , 1991, Life sciences.

[41]  Kjell Hole,et al.  The formalin test in mice: dissociation between inflammatory and non-inflammatory pain , 1987, Pain.

[42]  C. Post,et al.  Behavioural and antinociceptive effects of intrathecally injected substance P analogues in mice. , 1985, European journal of pharmacology.

[43]  M. Zimmermann,et al.  Ethical guidelines for investigations of experimental pain in conscious animals , 1983, Pain.

[44]  J. Henry,et al.  Effects of substance P on functionally identified units in cat spinal cord , 1976, Brain Research.